BenzaMide, N-[4-[(4-ethyl-1-piperazinyl)Methyl]-3-(trifluoroMethyl)phenyl]-4-Methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]aMino]-
- Product Name
- BenzaMide, N-[4-[(4-ethyl-1-piperazinyl)Methyl]-3-(trifluoroMethyl)phenyl]-4-Methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]aMino]-
- CAS No.
- 1186206-79-0
- Chemical Name
- BenzaMide, N-[4-[(4-ethyl-1-piperazinyl)Methyl]-3-(trifluoroMethyl)phenyl]-4-Methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]aMino]-
- Synonyms
- CS-2709;ALW-II-41-27;Reaxys ID: 20109046;Eph receptor tyrosine kinase inhibitor;ALWII4127,Inhibitor,inhibit,Ephrin Receptor,ALW II 41 27;N-(5-((4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)-2-methylphenyl)-5-(thiophen-2-yl)nicotinamide;BenzaMide, N-[4-[(4-ethyl-1-piperazinyl)Methyl]-3-(trifluoroMethyl)phenyl]-4-Methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]aMino]-;BenzaMide, N-[4-[(4-ethyl-1-piperazinyl)Methyl]-3-(trifluoroMethyl)phenyl]-4-Methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]aMino]- USP/EP/BP
- CBNumber
- CB82666585
- Molecular Formula
- C32H32F3N5O2S
- Formula Weight
- 607.69
- MOL File
- 1186206-79-0.mol
BenzaMide, N-[4-[(4-ethyl-1-piperazinyl)Methyl]-3-(trifluoroMethyl)phenyl]-4-Methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]aMino]- Property
- Boiling point:
- 612.3±55.0 °C(Predicted)
- Density
- 1.321±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- ≥60.8 mg/mL in EtOH; insoluble in H2O; ≥102 mg/mL in DMSO
- form
- Powder
- pka
- 11.66±0.70(Predicted)
- color
- White to light yellow
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- 25275
- Product name
- ALW-II-41-27
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $62
- Updated
- 2024/03/01
- Product number
- 25275
- Product name
- ALW-II-41-27
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $270
- Updated
- 2024/03/01
- Product number
- 25275
- Product name
- ALW-II-41-27
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $477
- Updated
- 2024/03/01
- Product number
- 9809DD
- Product name
- Alw-II-41-27
- Packaging
- 1mg
- Price
- $166
- Updated
- 2021/12/16
- Product number
- CS-1203
- Product name
- ALW-II-41-27
- Purity
- 99.70%
- Packaging
- 5mg
- Price
- $210
- Updated
- 2021/12/16
BenzaMide, N-[4-[(4-ethyl-1-piperazinyl)Methyl]-3-(trifluoroMethyl)phenyl]-4-Methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]aMino]- Chemical Properties,Usage,Production
Biological Activity
alw-ii-41-27 is a potent inhibitor of eph family kinases, with an ic50 value of 11 nm to epha2 [1] [2].eph family proteins are key regulators of both disease and normal development. eph receptors are involved in many intracellular signaling pathways such as pi3k/akt/mtor, ras/raf/mapk, fak, src, abl, and rho/rac/cdc42 [2].in h358 cells, treatment with alw-ii-41-27 at a concentration of 1 μm within 15 minutes impaired the tyrosine phosphorylation of the epha2 receptor and continued to inhibit the tyrosine phosphorylation through 6 hours. alw-ii-41-27 also dose-dependently inhibited the epha2 phosphorylation induced by ligand. when the epha2 was depleted by rnai in nsclc cell lines, cells were much less sensitive to alw-ii-41-27.it was suggested that epha2 plays an oncogenic role according to results in lung cancers. in mice bearing non–small cell lung cancers (nsclcs), intraperitoneal injection with alw-ii-41-27 at a dose of 15 mg/kg twice daily for 14 days significantly resulted in an inhibition of the growth of h358 tumors. alw-ii-41-27 significantly increased the apoptosis of tumors compared with the vehicle alone or ng-25. this was similar to the effect of the genetic ablation of epha2. compared with treatments with vehicle alone or ng-25, treatment with alw-ii-41-27 did not result in significant differences in the vessel density or proliferation of tumors [2].
References
[1]. marialuisa moccia, qingsong liu, teresa guida, et al. identification of novel small molecule inhibitors of oncogenic ret kinase. plos one, 2015, 10(6):e0128364.
[2]. katherine r. amato, shan wang, andrew k. hastings, et al. genetic and pharmacologic inhibition of epha2 promotes apoptosis in nsclc. journal of clinical investigation, 2014, 124(5):2037-2049.
BenzaMide, N-[4-[(4-ethyl-1-piperazinyl)Methyl]-3-(trifluoroMethyl)phenyl]-4-Methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]aMino]- Preparation Products And Raw materials
Raw materials
Preparation Products
BenzaMide, N-[4-[(4-ethyl-1-piperazinyl)Methyl]-3-(trifluoroMethyl)phenyl]-4-Methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]aMino]- Suppliers
- Tel
- Fax
- 86-21-57758967
- sales@boylechem.com
- Country
- China
- ProdList
- 2922
- Advantage
- 55
- Tel
- 021-58950125
- Fax
- (86) 21-58955996
- info@chemexpress.com
- Country
- China
- ProdList
- 7552
- Advantage
- 61
- Tel
- 400-400-6206333 18521732826
- Fax
- 021-50323701
- market@aladdin-e.com
- Country
- China
- ProdList
- 25003
- Advantage
- 65
- Tel
- 18149758185 18149758185
- sales-cpd@caerulumpharma.com
- Country
- China
- ProdList
- 3466
- Advantage
- 58
- Tel
- 400-0066400 13621662912
- Fax
- 021-55660885
- 422131432@qq.com
- Country
- China
- ProdList
- 9978
- Advantage
- 55
- Tel
- +86-21-5821 5861
- Fax
- +86-21-5106 2861
- sales@letopharm.com
- Country
- China
- ProdList
- 2384
- Advantage
- 58
- Tel
- 021-52996696，15000506266 15000506266
- Fax
- +86-21-52996696
- Country
- China
- ProdList
- 4566
- Advantage
- 55
- Tel
- Fax
- -
- eric_feng1954@126.com
- Country
- China
- ProdList
- 9248
- Advantage
- 55
- Tel
- 021-60546673 13701861782
- Fax
- QQ:670259431
- kuanga111@sina.com
- Country
- China
- ProdList
- 822
- Advantage
- 58
- Tel
- 18620099427
- Fax
- +86-20-62619665
- amy@howeipharm.com
- Country
- China
- ProdList
- 17687
- Advantage
- 55